CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc., a company leading the discovery and development of targeted therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in two upcoming conferences:
- Robert Gould, Ph.D., President and CEO, will participate on a private financing panel at the Boston Biotech CEO Conference on June 21 from 9:30-10:00am.
- Jason P. Rhodes, EVP and Chief Business Officer, will speak on the “Disco Inferno – Pharma Feels the Heat with Discovery Deals,” panel at the BIO International Convention on June 27 from 3:45-5:00pm.
Epizyme’s therapeutics discovery programs are focused on histone methyltransferases (HMTs), a class of epigenetic enzymes that play an important role in regulating pathways of genes that are strongly associated with the underlying causes of many human diseases, including cancer. Epizyme announced a program-based partnership with Eisai for the epigenetic enzyme EZH2 in March 2011 and a multi-target drug discovery alliance with GlaxoSmithKline in January 2011.
Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of targeted therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. www.epizyme.com
MacDougall Biomedical Communications
Jennifer Conrad or Chris Erdman, 781-235-3060
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical